Abstract
Evidence suggests that T lymphocyte-mediated inhibition of hematopoiesis in myelodysplastic syndrome (MDS) contributes to cytopenia in some patients and can be reversed by treatment with immunosuppression. We examined the T-cell repertoires of 12 patients with MDS before and after antithymocyte globulin (ATG)-based treatment by T-cell receptor Vβ (TCR-Vβ) spectratype analysis. The average number of TCR-Vβ families with skewed spectratypes, representative of clonal or oligoclonal T-cell populations, was 7.6 in MDS patients before treatment and 3.2 in healthy controls (P = .02). Four patients who recovered effective hematopoiesis after treatment lost prominent, skewed peaks on their spectratypes, suggesting loss or diminution of overrepresented clonal T-cell populations. In contrast, patients who did not recover effective hematopoiesis showed persistently skewed repertoires 3 to 6 months after treatment. In 3 patients with skewed repertoires, cDNA from the complementarity-determining region 3 (CDR3) of 4 TCR-Vβ families was cloned and repetitively sequenced, confirming clonal T-cell dominance in each family. In one nonresponder, 16 of 19 CDR3 sequences were identical, demonstrating that 9.3% of the total T-cell population was made up of a single clone. By 6 months after treatment, this clone persisted on both spectratype and DNA sequence complementarity and when analyzed by flow cytometry was shown to be CD8 +/CD45RA +/HLA -. T-cell clones were not anergic because they could be expanded 4-fold in vitro. Our results demonstrate that predominant clonal T cells that appear to be antigen-driven persist in patients with MDS unresponsive to immunosuppression, but predominant clones regress in responders to immunosuppression.
| Original language | English |
|---|---|
| Pages (from-to) | 3639-3645 |
| Number of pages | 7 |
| Journal | Blood |
| Volume | 100 |
| Issue number | 10 |
| DOIs | |
| State | Published - Nov 15 2002 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Hematology
Cite this
Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. / Kochenderfer, James N.; Kobayashi, Sumiko; Wieder, Eric; Su, Chunliu; Molldrem, Jeffrey J.
In: Blood, Vol. 100, No. 10, 15.11.2002, p. 3639-3645.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression
AU - Kochenderfer, James N.
AU - Kobayashi, Sumiko
AU - Wieder, Eric
AU - Su, Chunliu
AU - Molldrem, Jeffrey J.
PY - 2002/11/15
Y1 - 2002/11/15
N2 - Evidence suggests that T lymphocyte-mediated inhibition of hematopoiesis in myelodysplastic syndrome (MDS) contributes to cytopenia in some patients and can be reversed by treatment with immunosuppression. We examined the T-cell repertoires of 12 patients with MDS before and after antithymocyte globulin (ATG)-based treatment by T-cell receptor Vβ (TCR-Vβ) spectratype analysis. The average number of TCR-Vβ families with skewed spectratypes, representative of clonal or oligoclonal T-cell populations, was 7.6 in MDS patients before treatment and 3.2 in healthy controls (P = .02). Four patients who recovered effective hematopoiesis after treatment lost prominent, skewed peaks on their spectratypes, suggesting loss or diminution of overrepresented clonal T-cell populations. In contrast, patients who did not recover effective hematopoiesis showed persistently skewed repertoires 3 to 6 months after treatment. In 3 patients with skewed repertoires, cDNA from the complementarity-determining region 3 (CDR3) of 4 TCR-Vβ families was cloned and repetitively sequenced, confirming clonal T-cell dominance in each family. In one nonresponder, 16 of 19 CDR3 sequences were identical, demonstrating that 9.3% of the total T-cell population was made up of a single clone. By 6 months after treatment, this clone persisted on both spectratype and DNA sequence complementarity and when analyzed by flow cytometry was shown to be CD8 +/CD45RA +/HLA -. T-cell clones were not anergic because they could be expanded 4-fold in vitro. Our results demonstrate that predominant clonal T cells that appear to be antigen-driven persist in patients with MDS unresponsive to immunosuppression, but predominant clones regress in responders to immunosuppression.
AB - Evidence suggests that T lymphocyte-mediated inhibition of hematopoiesis in myelodysplastic syndrome (MDS) contributes to cytopenia in some patients and can be reversed by treatment with immunosuppression. We examined the T-cell repertoires of 12 patients with MDS before and after antithymocyte globulin (ATG)-based treatment by T-cell receptor Vβ (TCR-Vβ) spectratype analysis. The average number of TCR-Vβ families with skewed spectratypes, representative of clonal or oligoclonal T-cell populations, was 7.6 in MDS patients before treatment and 3.2 in healthy controls (P = .02). Four patients who recovered effective hematopoiesis after treatment lost prominent, skewed peaks on their spectratypes, suggesting loss or diminution of overrepresented clonal T-cell populations. In contrast, patients who did not recover effective hematopoiesis showed persistently skewed repertoires 3 to 6 months after treatment. In 3 patients with skewed repertoires, cDNA from the complementarity-determining region 3 (CDR3) of 4 TCR-Vβ families was cloned and repetitively sequenced, confirming clonal T-cell dominance in each family. In one nonresponder, 16 of 19 CDR3 sequences were identical, demonstrating that 9.3% of the total T-cell population was made up of a single clone. By 6 months after treatment, this clone persisted on both spectratype and DNA sequence complementarity and when analyzed by flow cytometry was shown to be CD8 +/CD45RA +/HLA -. T-cell clones were not anergic because they could be expanded 4-fold in vitro. Our results demonstrate that predominant clonal T cells that appear to be antigen-driven persist in patients with MDS unresponsive to immunosuppression, but predominant clones regress in responders to immunosuppression.
UR - http://www.scopus.com/inward/record.url?scp=0037111548&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037111548&partnerID=8YFLogxK
U2 - 10.1182/blood-2002-01-0155
DO - 10.1182/blood-2002-01-0155
M3 - Article
C2 - 12393644
AN - SCOPUS:0037111548
VL - 100
SP - 3639
EP - 3645
JO - Blood
JF - Blood
SN - 0006-4971
IS - 10
ER -